STVN$23.68
Chart
Performance
Key Stats
AI STVN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyStevanato Group shows strong fundamental performance with positive growth trends and a solid financial position. While thematic tailwinds are present in healthcare and biopharma packaging, short-term technicals indicate a recent uptick with potential for continued momentum. Valuation is somewhat extended, warranting careful consideration.
Thematic
Stevanato Group is well-positioned to benefit from the growing healthcare and biopharmaceutical sectors, driven by increased demand for drug containment and delivery solutions.
Fundamental
The company exhibits solid revenue growth, improving profitability metrics, and a healthy balance sheet. However, the latest quarterly results show a dip in net margin and negative free cash flow, which warrant monitoring.
Technical
The stock is exhibiting strong positive momentum across multiple timeframes, with price trading above key moving averages and most oscillators indicating bullish sentiment. Recent price action shows a significant increase.
| Factor | Score |
|---|---|
| Healthcare & Biopharma Demand | 90 |
| Diagnostic Solutions Growth | 85 |
| Drug Delivery Innovation | 88 |
| Market Diversification | 70 |
| Sustainability & ESG | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 70 |
| Growth | 55 |
| Balance Sheet Health | 85 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 95 |
| Momentum | 75 |
| Volume Confirmation | 80 |
| Short-Term Oscillators | 85 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent Performance
The stock has shown significant positive performance across multiple short to medium-term periods, with a 5-day return of 15.64%, a 1-month return of 11.4%, and a 6-month return of 32.21%. Year-to-date performance stands at 24.89%.
Positive Valuation Trends
While trailing P/E is high (51.76), the forward P/E (implied by the 2024 estimated P/E of 9.2) indicates a significant expected improvement in earnings, potentially making the stock attractive on a forward-looking basis.
Bearish Points (7)
High Current Valuation Metrics
The current Price-to-Earnings (P/E) ratio of 51.76 is significantly high, and the Price-to-Sales (P/S) ratio of 8.8 (TTM) suggests the market has high expectations for future performance that may be difficult to meet.
Negative Free Cash Flow
The company has reported negative free cash flow for the last three annual periods (2024: -$157.8M, 2023: -$336.7M, 2022: -$139.8M), indicating it is spending more cash than it is generating after capital expenditures.
Calendar
June 2025
5
Ex-Dividend Date
July 2025
17
Next Dividend Date
August 2025
5
Next Earnings Date
H: $0.14
A: $0.12
L: $0.10
H: 273.11M
A: 268.25M
L: 260.20M
Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Seasonals
Price Target
28.02 USD
The 39 analysts offering 1 year price forecasts for STVN have a max estimate of 37.00 and a min estimate of 23.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor and key peer in injectable drug containment and delivery components, specializing in stoppers, plungers, and seals.
Weight: 95
Direct competitor in pharmaceutical glass and plastic packaging, syringes, and drug delivery systems, serving similar client bases.
Weight: 90
Direct competitor focused on high-quality pharmaceutical glass packaging, including vials, syringes, and cartridges for injectable drugs.
Weight: 88
Leading contract development and manufacturing organization (CDMO) with significant sterile fill-finish, advanced drug delivery, and packaging capabilities.